ALXO ALX ONCOLOGY HLDGS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ALX ONCOLOGY HLDGS INC reported revenue of n/a, net income of −$18.0M and diluted EPS of −$0.13; for the fiscal year ended December 2025 revenue was n/a.
ALXO annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$104M, net income −$102M (margin n/a), EPS −$1.90
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$142M, net income −$135M (margin n/a), EPS −$2.58
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$170M, net income −$161M (margin n/a), EPS −$3.74
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$127M, net income −$123M (margin n/a), EPS −$3.03
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$83.6M, net income −$83.5M (margin n/a), EPS −$2.07
ALXO quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$18.0M, EPS −$0.13
- Quarter ended Mar 31, 2026: revenue n/a, net income −$17.9M, EPS −$0.17
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$22.8M, EPS −$0.42
- Quarter ended Sep 30, 2025: revenue n/a, net income −$22.1M, EPS −$0.41
- Quarter ended Jun 30, 2025: revenue n/a, net income −$25.9M, EPS −$0.49
- Quarter ended Mar 31, 2025: revenue n/a, net income −$30.8M, EPS −$0.58
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$29.2M, EPS −$0.53
- Quarter ended Sep 30, 2024: revenue n/a, net income −$30.7M, EPS −$0.58
- Quarter ended Jun 30, 2024: revenue n/a, net income −$39.4M, EPS −$0.76
- Quarter ended Mar 31, 2024: revenue n/a, net income −$35.6M, EPS −$0.71
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$45.5M, EPS −$0.92
- Quarter ended Sep 30, 2023: revenue n/a, net income −$51.0M, EPS −$1.24
- Quarter ended Jun 30, 2023: revenue n/a, net income −$34.2M, EPS −$0.84
- Quarter ended Mar 31, 2023: revenue n/a, net income −$30.2M, EPS −$0.74
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$30.7M, EPS −$0.75
- Quarter ended Sep 30, 2022: revenue n/a, net income −$35.3M, EPS −$0.87
- Quarter ended Jun 30, 2022: revenue n/a, net income −$32.9M, EPS −$0.81
- Quarter ended Mar 31, 2022: revenue n/a, net income −$24.5M, EPS −$0.60
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$28.4M, EPS −$0.71
- Quarter ended Sep 30, 2021: revenue n/a, net income −$24.6M, EPS −$0.61
ALXO cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$84.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$122M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$130M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$89.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$68.1M, share buybacks n/a
ALXO balance sheet
- Jun 30, 2026: cash $22.7M, total assets $161M, total liabilities $24.6M, shareholders' equity $136M, long-term debt $9.71M
- Mar 31, 2026: cash $32.3M, total assets $178M, total liabilities $27.0M, shareholders' equity $151M, long-term debt $3.30M
- Dec 31, 2025: cash $16.4M, total assets $59.0M, total liabilities $33.1M, shareholders' equity $26.0M, long-term debt $4.53M
- Sep 30, 2025: cash $23.4M, total assets $82.7M, total liabilities $37.9M, shareholders' equity $44.8M, long-term debt $5.76M
- Jun 30, 2025: cash $19.3M, total assets $95.3M, total liabilities $30.9M, shareholders' equity $64.4M, long-term debt $7.00M
- Mar 31, 2025: cash $20.6M, total assets $121M, total liabilities $32.6M, shareholders' equity $88.3M, long-term debt $8.23M
- Dec 31, 2024: cash $17.6M, total assets $148M, total liabilities $34.2M, shareholders' equity $114M, long-term debt $9.47M
- Sep 30, 2024: cash $16.1M, total assets $186M, total liabilities $48.9M, shareholders' equity $137M, long-term debt $9.84M
Is ALXO profitable?
No. ALX ONCOLOGY HLDGS INC lost $80.9M over the last four quarters.
What is ALXO's EPS?
Diluted earnings per share over the last four quarters were −$1.13; −$0.13 in the latest quarter.